Cosentyx (secukinumab)

P=N/A, N=142, Not yet recruiting, Novartis Pharmaceuticals

P3, N=151, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jul 2026 --> Jan 2026

Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab, 13.8 (9.10-20.1) for risankizumab and 17.2 (7.43-33.9) for tildrakizumab...In this analysis, we observed a low incidence of serious infections across treatment groups. The Cox proportional hazards analysis with propensity scores and inverse probability treatment weighting to account for differences in potential confounders would provide further insights into the relative risk of serious infection.

P3, N=151, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2026 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Feb 2026

P=N/A, N=127, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

After 3 months of treatment, the cutaneous lesions had substantially resolved, with no reported adverse effects. Anti-IL-17A monoclonal antibody therapy may represent an alternative treatment modality for cGVHD patients presenting with psoriatic phenotypes.

P1, N=114, Not yet recruiting, Taizhou Mabtech Pharmaceutical Co.,Ltd

P=N/A, N=76, Not yet recruiting, Novartis Pharmaceuticals

P1, N=4, Not yet recruiting, Duke University

Both patients completed 9 months of anti-TB treatment without adverse events or TB reactivation during 1 year follow-up. These observations suggest that secukinumab may be a safe and effective therapeutic option for patients with AS with concomitant active TB when anti-TNF agents are contraindicated, though confirmation in larger studies is warranted.

CPR analyses based on MAIC response rates at week 52 suggest that bimekizumab is more cost-efficient than IL-12/23 and IL-23 therapies, including ustekinumab, guselkumab and risankizumab, for treating PsA in Spain across both bDMARD-naïve patients and patients with TNFi-IR for all outcomes (MDA, ACR50/70). Compared to IL-17A (secukinumab), bimekizumab is consistently cost-efficient in patients with TNFi-IR for all outcomes and is cost-efficient in bDMARD-naïve patients versus those taking 300 mg regarding MDA and ACR70.

P3, N=300, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2028 --> Aug 2028 | Trial primary completion date: Feb 2028 --> Aug 2028